Skip to main content

Siga Technologies

SIGA Technologies Inc is an American commercial-stage pharmaceutical company specializing in health security and antiviral countermeasures for orthopoxviruses including smallpox, mpox, and cowpox. The company commercializes TPOXX (tecovirimat), an FDA-approved antiviral treatment available in oral and intravenous formulations, stockpiled by government biodefense agencies globally. Principal revenues derive from government procurement contracts for biodefense stockpiling, notably with the US Strategic National Stockpile (BARDA) and international health ministries. Core end markets encompass national defense agencies, public health ministries, biodefense stockpiling programs, and emergency medical responders across the United States, Canada, Europe, and international allies. SIGA Technologies holds a market-leading position globally as the primary developer and supplier of targeted smallpox and orthopoxvirus antiviral therapeutics. The corporation is headquartered in New York, New York, and its common stock trades on the Nasdaq Global Market.

2 of the funds FundTelligence covers report a position in Siga Technologies.

Legal name
SIGA TECHNOLOGIES INC
Sector
Health Care
Country
United States
Funds holding it
2

Funds holding Siga Technologies

Loading...